Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
|Videos|April 21, 2011
Ted Okon on When the VBID Will be Implemented
Author(s)Ted Okon
Ted Okon the Executive Director of the Community Oncology Alliance (COA) on When the Value-Based Insurance Design Will be Implemented
Advertisement
Ted Okon the Executive Director of the Community Oncology Alliance (COA) on When the Value-Based Insurance Design Will be Implemented
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
The OncFive: Top Oncology Articles for the Week of 7/19
5